Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Free Cash Flow (2023 - 2025)

Immunome's Free Cash Flow history spans 3 years, with the latest figure at -$47.7 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 7.64% year-over-year to -$47.7 million; the TTM value through Dec 2025 reached -$191.9 million, down 68.95%, while the annual FY2025 figure was -$191.9 million, 68.95% down from the prior year.
  • Free Cash Flow reached -$47.7 million in Q4 2025 per IMNM's latest filing, down from -$40.5 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $24.1 million in Q1 2023 to a low of -$53.6 million in Q1 2025.
  • Average Free Cash Flow over 3 years is -$26.1 million, with a median of -$28.0 million recorded in 2024.
  • The largest YoY upside for Free Cash Flow was 7.64% in 2025 against a maximum downside of 302.33% in 2025.
  • A 3-year view of Free Cash Flow shows it stood at -$17.3 million in 2023, then crashed by 155.49% to -$44.3 million in 2024, then fell by 7.64% to -$47.7 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Free Cash Flow are -$47.7 million (Q4 2025), -$40.5 million (Q3 2025), and -$50.1 million (Q2 2025).